Stock DNA
Pharmaceuticals & Biotechnology
CNY 3,576 Million (Small Cap)
164.00
NA
0.00%
0.35
5.26%
8.60
Revenue and Profits:
Net Sales:
48 Million
(Quarterly Results - Mar 2026)
Net Profit:
-1 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
9.71%
0%
9.71%
6 Months
21.51%
0%
21.51%
1 Year
17.89%
0%
17.89%
2 Years
103.27%
0%
103.27%
3 Years
52.1%
0%
52.1%
4 Years
68.93%
0%
68.93%
5 Years
105.19%
0%
105.19%
Hainan Shuangcheng Pharmaceuticals Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-0.72%
EBIT Growth (5y)
19.07%
EBIT to Interest (avg)
-6.17
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.46
Sales to Capital Employed (avg)
0.33
Tax Ratio
0.09%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
164
Industry P/E
Price to Book Value
8.60
EV to EBIT
128.05
EV to EBITDA
52.52
EV to Capital Employed
6.61
EV to Sales
12.97
PEG Ratio
1.33
Dividend Yield
NA
ROCE (Latest)
5.16%
ROE (Latest)
5.26%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
48.40
107.90
-55.14%
Operating Profit (PBDIT) excl Other Income
2.50
32.90
-92.40%
Interest
2.30
2.40
-4.17%
Exceptional Items
0.10
-0.40
125.00%
Consolidate Net Profit
-0.60
16.20
-103.70%
Operating Profit Margin (Excl OI)
52.40%
173.00%
-12.06%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -55.14% vs 27.24% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is -103.70% vs 2.53% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
275.70
168.40
63.72%
Operating Profit (PBDIT) excl Other Income
72.50
-16.30
544.79%
Interest
9.70
9.30
4.30%
Exceptional Items
-2.70
-29.00
90.69%
Consolidate Net Profit
8.90
-106.30
108.37%
Operating Profit Margin (Excl OI)
62.90%
-426.10%
48.90%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 63.72% vs -28.00% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 108.37% vs -47.64% in Dec 2024
About Hainan Shuangcheng Pharmaceuticals Co., Ltd. 
Hainan Shuangcheng Pharmaceuticals Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






